Healio

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a rare genetic ventricular tachycardia which can result in sudden cardiac death and/or syncope in young individuals with structurally ...
Yahoo Finance

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

CHARLESTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular ...
Nature

Clinical utility gene card for: Catecholaminergic polymorphic ventricular tachycardia (CPVT)

Two genes are clearly associated with CPVT (RyR2 autosomal dominant and CASQ2 autosomal recessive). Triadin and calmodulin mutations have been shown in possible CPVT cases and in one family with ...
Yahoo Finance

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

CHARLESTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a clinical stage life sciences company developing precision genetic medicines for neuromuscular and cardiac ...
Nasdaq

Solid Biosciences to Initiate Phase 1b Trial for SGT-501, a Novel Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia

Solid Biosciences announces Phase 1b trial for SGT-501, a gene therapy for catecholaminergic polymorphic ventricular tachycardia, with FDA designations. Solid Biosciences Inc. has announced the ...
News Medical

ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia

ARMGO Pharma, Inc. (ARMGO), a clinical stage biopharmaceutical company advancing a novel class of small molecule drugs known as Rycals®, announced today the enrollment of the first patient in a Phase ...
Pharmabiz

US FDA grants Fast Track designation to Solid Biosciences’ SGT-501, an AAV-based l gene therapy to treat catecholaminergic polymorphic ventricular tachycardia

Solid Biosciences Inc., a clinical stage life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that it received Fast Track designation from the ...
ABC 7 Chicago

High school athlete back on the football field months after going into cardiac arrest

CRESTON, Iowa -- Five months after collapsing at a spring track meet, 15-year-old Nate Bentley is back under the Friday night lights - this time with a personalized plan and a heart monitor helping ...
Seeking Alpha

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

- Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying causes of CPVT, a life-threatening, arrhythmogenic cardiac condition - - Solid ...
Medical Xpress

Polymorphic Catecholaminergic Ventricular Tachycardia

Researchers have developed a novel method for simultaneously recording action potentials (APs)—temporary changes in electrical potential when cells become excited—and calcium transients—calcium ...